Fallopian Tube Neoplasms  >>  pegylated liposomal doxorubicin  >>  Phase 3
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
pegylated liposomal doxorubicin / Generic mfg.
NCT02728622: Chemotherapy vs Hormonal Treatment in Platinum-resistant Ovarian Cancer Resistant or Refractory to Platinum and Taxane

Completed
3
241
Europe
Tamoxifen, Chemotherapy, paclitaxel, pegylated liposomal doxorubicin
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Ovarian Cancer, Peritoneal Cancer, Cancer of the Fallopian Tube
01/08
01/09
NCT00245050: Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer

Completed
3
34
US
pyridoxine hydrochloride, Placebo, doxorubicin HCL liposome
Case Comprehensive Cancer Center, National Cancer Institute (NCI)
Breast Cancer, Drug/Agent Toxicity by Tissue/Organ, Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
04/08
09/11
CALYPSO, NCT00189553: Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse

Completed
3
976
Europe
Pegylated liposomal doxorubicin, Caelyx, Carboplatin, generic drug, Paclitaxel
ARCAGY/ GINECO GROUP, Schering-Plough, Arbeitsgemeinschaft Gynaekologische Onkologie Austria, AGO Study Group, Australia New Zealand Gynaecological Oncology Group, European Organisation for Research and Treatment of Cancer - EORTC, NCIC Clinical Trials Group, NSGO
Ovarian Cancer, Fallopian Tube Cancer
01/09
06/12
TRINOVA-2, NCT01281254 / 2009-017946-30: AMG 386 (Trebananib) in Ovarian Cancer

Checkmark P3 trial (TRINOVA-2) enrollment discontinued due to Doxil supply issues
Mar 2014 - Mar 2014: P3 trial (TRINOVA-2) enrollment discontinued due to Doxil supply issues
Terminated
3
223
US, Canada, Europe, RoW
AMG386 plus PLD, Placebo plus PLD
Amgen
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer
08/14
04/17
NCT01846611 / 2012-004808-34: A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Completed
3
581
US, Europe, RoW
Trabectedin, DOXIL, Dexamethasone
Janssen Research & Development, LLC, PharmaMar
Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms
01/18
11/18

Download Options